Two unexpected phenomena in macrolide-resistant Mycoplasma pneumoniae infection in Japan and the unique biological characteristics of Mycoplasma pneumoniae

Journal of Infection and Chemotherapy

Volumn 17, Issue 5, 2011, Pages 735-736

  Narita, Mitsuo ^a  

^a Sapporo Tokushukai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RNA 23S; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL SHEDDING; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; JAPAN; LETTER; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; OPERON; PLASMID; POINT MUTATION; PREVALENCE; PROTEIN SYNTHESIS; RESPIRATORY FAILURE; RIBOSOME;

EID: 84855454869     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0235-0     Document Type: Letter

References (3)

1. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients with over 18 years. J Infect Chemother. 2011;17:114-8.
2. Schmidl SR, Hames C, Stülke J. Expression of Mycoplasma proteins carrying an affinity tag in M. pneumoniae allows rapid purification and circumvents problems related to the aberrant genetic code. Appl Environ Microbiol. 2007;73:7799-801.
3. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li B-C, Herrmann R. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. Nucleic Acids Res. 1996;24:4420-49. (Pubitemid 26388629)